After lackluster activity in the past years, pharmaceutical firms have gotten back to producing new drugs but they encounter challenges in selling them, according to a report on The Wall Street Journal.
Johnson & Johnson
California, US-based software developing company Accelrys has acquired Ireland-based software business Qumas in a deal valued at $50 million to expand its products expansion and client base.
Washington-based tech company Microsoft Corp sold a record offering of USD8 billion of bonds in dollars and euros to fund general corporate purposes, according to regulatory filings today.
Top credit ranking Johnson & Johnson reportedly sold USD3.5 billion in a six-part bond issue, its first offering in the last two years. Proceeds from the deal will be used to pay the health care product manufacturer's outstanding debt.
US-based generic drug manufacturer Mylan and two Indian pharmaceutical firms are in talks to buy Chennai-based Bafna Pharmaceuticals for an undisclosed amount, according to two sources familiar with the transaction.
Only three potential buyers from at least five who expressed initial interest were left to bid for the Ortho Clinical Diagnostics business of healthcare firm Johnson & Johnson, according to sources interviewed by Bloomberg.
Sources name the Carlyle Group LP and a combined group from Danaher Corp and Blackstone Group LP to have successfully advanced to the final stage of sale negotiations for J&J's diagnostics unit
Many private equity firms and partnerships are in the process of formulating their bids for diagnostic unit of Johnson&Johnson.
Johnson & Johnson received numerous preliminary offers from hedge funds interested in acquiring its Ortho Clinical Diagnostics unit, said a Reuters report.
Johnson & Johnson had launched a sale process for its Ortho Clinical Diagnostics unit valued at USD5 billion.
Energizer Holdings planned to acquire Johnson & Johnson's feminine care line for US$185 million.
Kinetic Concepts Inc. revealed that they had signed an investment agreement to acquire Systagenix for US$485 million.
The privately held company gets deal with Johnson & Johnson Development Corporation and New Enterprise Associates as co-lead investors.
Johnson & Johnson announced that it would pay US$1 billion to Aragon Pharmaceuticals and its experimental drugs for prostate cancer treatment.
Elan Pharmaceuticals has decided to sell itself after the many tendered offers it has received.
Subscribe to VCpost newsletter
Most Popular
- Tesla Shareholder Votes Against Elon Musk’s $55 Billion Pay Package, Says 'Tyrant CEO' Abandons EV Maker for His Other Firms
- IMF Criticizes Joe Biden's Ramping Up Chinese Import Tariffs, Says US Should Work With China to Resolve Disputes
- AT&T, Verizon, and T-Mobile to Pay $10 Million Settlement Over Misleading Claims About ‘Unlimited’ Plans
- Investment Banker at Bank of America Dies from Blood Clot, Cited 100-Hour Weeks as Reason for Wanting to Leave
- Silver Dethrones Gold Demand After Surpassing $30 an Ounce, Highest Level Since 2013
- Scam Warning: This is the Most Common Time People Were Likely to Get Victimized
- SNAP Benefits 2024: Storm-Affected Residents to Receive Replacement Applications, Extended Deadline
- Visa to Change Credit, Debit Card Operations in US